VolitionRx Limited (NYSEAMERICAN:VNRX) CEO Cameron Reynolds tells Proactive it is actively developing a coronavirus triage test using its proprietary Nu.QTM platform. Reynolds says the test is being designed to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease. Results from a proof-of-concept study are expected by the end of May.
VolitionRx developing a proprietary coronavirus triage test
Quick facts: VolitionRx
Price: 3.35 USD
Market Cap: $154.86 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE